Ankylosing Spondylitis Treatment Market Size

Global Ankylosing Spondylitis Treatment Market size was valued at USD 4.70 Billion in 2023 poised to grow from USD 4.92 Billion in 2024 to USD 7.14 Billion by 2032, growing at a CAGR of 4.75% in the forecast period (2025-2032).

The growing global incidence of ankylosing spondylitis (AS) among young adults and middle-aged adults is the key driver for market growth. AS is an autoimmune, progressive, chronic disorder that mainly influences the spine and sacroiliac joints to cause severe pain and disability when left untreated. Genetic factors like the HLA-B27 gene play a major role in causing regional incidence rates, especially in Europe, North America, and certain areas of Asia. With increased awareness, diagnostic capacity, and screening activities, more patients are being diagnosed earlier. With this increasing pool of patients, long-term management is required, thus increasing demand for effective and innovative treatment worldwide.

Biologic therapy has become a mainstay of ankylosing spondylitis therapy with the advantage of targeting pathways of inflammation with more specificity than conventional drugs. Tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) blockers are particularly useful in the reduction of spinal inflammation and arrest of disease activity. Their success in clinical trials has been followed by widespread acceptance among practitioners, enhancing patient outcomes and satisfaction. In addition, continued research is aimed at creating next-generation biologics with reduced side effects and improved delivery methods. These developments are increasing therapeutic choices, driving investment, and strengthening the significance of biologics as a key driver in market growth.

How is AI Transforming the Ankylosing Spondylitis Treatment Landscape?

Artificial intelligence (AI) is largely driving the treatment market for ankylosing spondylitis (AS) across the globe through improving accuracy of diagnosis and customizing treatment regimes. Machine learning and deep learning models in AI algorithms excel in examining voluminous data, like MRI reports, genetic marker records, and patient history files, to discover prodromes (early indication) of AS like sacroiliitis, which may fail conventional diagnostic checks. For example, AI systems have been designed to aid in diagnosing and forecasting the course of AS, particularly in areas with limited expert clinicians. This technological innovation results in earlier treatments, better patient outcomes, and a greater need for targeted treatments, thus driving market growth.

In early 2025, researchers developed VertXGradeNet, an AI-based tool to automate spinal X-ray scoring for ankylosing spondylitis (AS) based on the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). VertXGradeNet predicts mSASSS scores based on vertebral units from cervical and lumbar X-rays, with the goal of simplifying the assessment process. This development responds to the labor-intensive process of manual scoring, hopefully improving diagnostic efficiency and consistency in AS care.

Why are Startups Key to Advancing Personalized Medicine in AS Treatment?

The global ankylosing spondylitis treatment market is evolving with the emergence of tech-enabled startups over the last decade. These firms are filling gaps in diagnosis, biologics discovery, and individualized medicine. Hinging on AI, precision immunology, and new targets, startups are confronting chronic inflammation and structural damage at the molecular level. Their nimble R&D models and high-impact discoveries are accelerating treatment pipelines, rewriting traditional strategies, and expanding the global therapeutic market.

Founded in 2021, Infinimmune is a U.S. biotech start-up established in 2021, which focuses on creating fully human monoclonal antibodies with state-of-the-art single-cell immune profiling. A central product is a targeted antibody candidate for autoimmune disease such as ankylosing spondylitis, which can modulate inflammatory cytokines with high precision. Its R&D innovation is through the harvesting of native antibodies directly from healthy immune repertoires. Its platform enhances treatment specificity, lowering the side effects and accelerating the clinical pipeline towards safer, highly efficient AS treatments.

Established in the year 2020, Sudo Biosciences, launched in 2020 in the U.S., focuses on small-molecule TYK2 inhibitors for autoimmune diseases, including ankylosing spondylitis. A standout product is a selective TYK2 inhibitor focused on modulating inflammatory signaling with minimal immune suppression. Their game-changing technology—a proprietary scaffold technology for optimal kinase selectivity—lowers off-target toxicity. This cause-and-effect model facilitates safer, targeted AS therapy, particularly for patients who fail current biologics, and ensures long-term therapeutic sustainability.